ReproNovo

Private

LausanneHealthcare & Life Scienceshttps://repronovo.com/

Last Round

Series A

May 21, 2025

Total Funding Raised

$65M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ReproNovo is a biopharmaceutical company that develops innovative treatments for reproductive medicine and women's health.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

organ preservationorgan perfusionmachine perfusionhypothermic oxygenated perfusionmedical deviceorgan transportationex-vivo perfusionliver preservationtransplantation technologymedtechsingle-use deviceorgan procurement organizationsOPOtransplant centerscold perfusion

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ReproNovo Comps

Public and private peers based on sector, stage, and business model.

ReproNovo comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ReproNovo Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	May 21, 2025

View all Funding Rounds

Key People

Founding team and executive leadership

BingMei Hao

CFO Co-Founder

Founding Team

Joan-Carles Arce

Chief Scientific Medical Officer Co-Founder

Founding Team

Jean Marie Duvall

Co-Founder And CEO

Founding Team

ReproNovo Investors

Notable investors and investment history

ReproNovo investors
Investor	Rounds
ALSA Ventures	Series A
M Ventures	Series A, Seed
Ysios Capital	Series A
AXA IM Alts	Series A
BNP Paribas Asset Management	Series A
Jeito	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 18, 2026
Monthly visitors grew 291% MoM, reaching 1.6K.
May 21, 2025
$65M Series A round completed.

View all signals

ReproNovo Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

ReproNovo Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ReproNovo's valuation, stock price, and market status.

Firmographic Details

HeadquartersLausanne

Employee Range22

Year Founded2021

Last FundingMay 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.